Breaking News Headlines Today | Ground News

See every side of every news story

Eyewire+ image

News from Eyewire+

Eyewire+’s media bias is unknown. Ground News is unable to assign a bias rating and does not have ratings available from Ad Fontes Media, AllSides, and Media Bias/Fact Check.

Eyewire+’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Eyewire+

Where is Eyewire+ located?Eyewire+'s Website

Media Bias Ratings

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Eyewire+ News

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

Waltham, Massachusetts · Waltham

BVI Appoints Jim Hollingshead as President & Chief Executive Officer

75% Left coverage: 8 sources

WALTHAM, Mass., Jan. 19, 2026 (GLOBE NEWSWIRE) -- BVI, a global leader in the ophthalmic device market, announced today the appointment of Jim Hollingshead as President & Chief Executive Officer. Hollingshead succeeds Shervin Korangy, who will continue to serve as…See the Story

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

Abu Dhabi, United Arab Emirates · Abu Dhabi

Opus Genetics Launches Gene Therapy Clinical Trial for MERTK-related Retinitis Pigmentosa

100% Left coverage: 1 sources

The trial is funded through Abu Dhabi’s Healthcare Research and Innovation FundClinical development activities will commence at Cleveland Clinic Abu Dhabi in 2026MERTK-related retinitis pigmentosa affects an estimated 60,000 patients worldwide See the Story

FDA Approves Repeat Treatment Labeling for Glaukos’ iDose TR in Glaucoma

Aliso Viejo · Aliso Viejo

FDA Approves Repeat Treatment Labeling for Glaukos’ iDose TR in Glaucoma

Glaukos announced that the FDA has approved a new drug application (NDA) labeling supplement for iDose TR that allows for re-administration using a repeat treatment protocol. The FDA approval follows Glaukos’ 2025 NDA labeling supplement submission and is supported by accumulated clinical evidence demonstrating the safety and tolerability of repeat use of iDose TR. According to Glaukos, the updated labeling provides physicians with additional fl…See the Story

Breaking News Topics Related to Eyewire+